Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) released its new scientific publication on Tuesday titled, "Medical Cannabis for Patients Over Age 50: A Multi-Site, Prospective Study of Patterns of Use and Health Outcomes."

The new research builds on a separate Tilray study that found that older patients comprise a growing subset of medical marijuana patients. That study found that patients with chronic pain (27.8%), arthritis (14.9%) and anxiety (9%) were the most numerous among those seeking cannabis to treat their primary illnesses. Pain was the most common primary symptom followed by anxiety and insomnia/sleep disorder, according to the study.

The Medical Cannabis in Older Patients Study is a multi-site, prospective, observational study examining the real-world impact of medical marijuana use on patients over 50 and under the guidance of a healthcare provider. It presented to the medical and scientific community the impact of medical cannabis on health outcomes. The main focus was on pain, sleep and quality of life.

Read Also: Tilray Medical Joins Fight Against Deadly Brain Tumors, Here's What's Happening

The study included 299 participants with an average age of 66.7 years, while 62.2% of respondents identified as female.

The results suggested that roughly 90% of patients have used medical cannabis to treat pain-related conditions, such as chronic pain and arthritis.

Moreover, MCOPs correlated with improvements in pain scores, sleep and quality of life in a still-growing subset of patients, while a significant reduction in co-medication was observed.

"Our involvement in this initiative underscores our unwavering commitment to advancing medical research and highlights our dedication to providing products that support the findings of the comprehensive research that bring us one step closer to unlocking the full therapeutic potential of medical cannabis, especially reinforcing its role as a treatment option for an aging population," said José Tempero, the company's medical director.

• Tilray Launches $250M At-The-Market Program To Boost Acquisitions, Eyes Expansion With U.S. Cannabis Rescheduling

TLRY Price Action

Tilray's shares traded 0.86% higher at $1.76 per share during the pre-market session on Tuesday morning.

Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.